Notch1 signaling hyper-activation is sustained in about 60% of T-ALL patients by gain-of-function mutations occurring in NOTCH1 gene, which promote increased stability and ligand-independent release of the N1ICD (4). This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.